tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Sarepta Therapeutics Refinances Convertible Senior Notes
PremiumCompany AnnouncementsSarepta Therapeutics Refinances Convertible Senior Notes
30d ago
Wedbush bullish on Sarepta, initiates with an Outperform
Premium
The Fly
Wedbush bullish on Sarepta, initiates with an Outperform
1M ago
Sarepta initiated with an Outperform at Wedbush
Premium
The Fly
Sarepta initiated with an Outperform at Wedbush
1M ago
Sarepta gets FDA approval to test Elevidys regimen in non-ambulant patients
PremiumThe FlySarepta gets FDA approval to test Elevidys regimen in non-ambulant patients
2M ago
Cautious Outlook on Sarepta Therapeutics Amid Early-Stage Trials and Financial Commitments
Premium
Ratings
Cautious Outlook on Sarepta Therapeutics Amid Early-Stage Trials and Financial Commitments
2M ago
Sarepta price target raised to $20 from $18 at Bernstein
Premium
The Fly
Sarepta price target raised to $20 from $18 at Bernstein
2M ago
Cautious Hold Rating on Sarepta Therapeutics Amid Elevidys Label Updates and Safety Concerns
PremiumRatingsCautious Hold Rating on Sarepta Therapeutics Amid Elevidys Label Updates and Safety Concerns
2M ago
Sell Rating for Sarepta Therapeutics Amid Label Changes and Market Challenges
Premium
Ratings
Sell Rating for Sarepta Therapeutics Amid Label Changes and Market Challenges
2M ago
Sarepta confirms FDA approval of updated Elevidys prescribing information
Premium
The Fly
Sarepta confirms FDA approval of updated Elevidys prescribing information
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100